普伐他汀对冠心病患者血脂血浆Chemerin水平超敏C反应蛋白血清脂联素影响.docVIP

普伐他汀对冠心病患者血脂血浆Chemerin水平超敏C反应蛋白血清脂联素影响 　　[摘要] 目的 探讨普伐他汀对冠心病患者血脂、血浆脂肪因子趋化素（Chemerin）水平、超敏C反应蛋白（hs-CRP）、血清脂联素的影响。 方法 收集2010年1月～2013年12月湖北省荣军医院老年病科收治的118例冠心病患者，并将其随机分为常规治疗组和普伐他汀组，观察治疗前后血浆Chemerin水平、hs-CRP、血清脂联素的变化，分析Chemerin、脂联素、hs-CRP与血脂浓度之间的相关性。 结果 疗程结束后，普伐他汀组血浆Chemerin、hs-CRP、总胆固醇（TC）、三酰甘油（TG）及低密度脂蛋白胆固醇（LDL-C）水平均较常规治疗组显著降低（P ＜ 0.01），血清脂联素及高密度脂蛋白胆固醇（HDL-C）水平均较常规治疗组显著升高（P ＜ 0.01）。血浆Chemerin与TG呈正相关（r = 0.48，P ＜ 0.01）；hs-CRP与HDL-C呈负相关（r = -0.21，P ＜ 0.01）；血清脂联素与HDL-C呈正相关（r = 0.56，P ＜ 0.01），与Chemerin、hs-CRP均呈负相关（r = -0.43、-0.36，P ＜ 0.01）。 结论 普伐他汀可以显著降低冠心病患者血脂水平，而且能提高血清脂联素水平以降低hs-CRP浓度及血浆Chemerin水平。 　　[关键词] 冠心病；普伐他汀；Chemerin；超敏C反应蛋白；脂联素 　　[中图分类号] R541.5[文献标识码] A[文章编号] 1673-7210（2014）05（c）-0072-03 　　 　　Influences of Pravastatin on blood lipid, plasma Chemerin, hs-CRP and serum adiponectin level in patients with coronary heart disease 　　ZHANG Xiaoping 　　Department of Geriatrics, Hubei Rongjun Hospital, Hubei Province, Wuhan 430079, China 　　[Abstract] Objective To investigate of blood lipid, plasma Chemerin, hs-CRP and serum adiponectin level in patients with coronary heart disease treated by Pravastatin. Methods 118 patients with coronary heart disease in Hubei Rongjun Hospital from January 2010 to December 2013 were collected and divided into trial group and control group randomly. Changes of blood lipid, plasma Chemerin, hs-CRP and serum adiponectin level were observed before and after treatment. Relationship of plasma Chemerin, serum levers of adiponectin and hs-CRP with blood lipid were observed. Results Level of plasma Chemerin, hs-CRP, TC, TG and LDL-C in trial group were significantly lower than control group (P ＜ 0.01). But serum adiponectin and HDL-C level of trial group were higher than control group (P ＜ 0.01). The plasma Chemerin concentration was significantly positively correlated with changes in TG (r = 0.48, P ＜ 0.01). And hs-CRP was significantly negatively correlated with changes in HDL-C (r = -0.21, P ＜ 0.01). The adiponectin was significantly pos